Quick Answer
NEKTAR THERAPEUTICS reported Earnings Per Share Diluted of $9.73 (loss) per share for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -12.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), NEKTAR THERAPEUTICS's Earnings Per Share Diluted has declined by 784.5%.
- Historical annual values: Fiscal year 2025: $9.73 (loss) per share | Fiscal year 2024: $8.68 (loss) per share | Fiscal year 2023: $1.45 (loss) per share | Fiscal year 2022: $1.97 (loss) per share | Fiscal year 2021: $2.86 (loss) per share | Fiscal year 2020: $2.49 (loss) per share | Fiscal year 2019: $2.52 (loss) per share | Fiscal year 2018: $3.78 per share | Fiscal year 2017: $0.62 (loss) per share | Fiscal year 2016: $1.10 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: